ExoTherapy platform

Search documents
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
Globenewswireยท 2025-05-02 20:05
Core Insights - NurExone Biologic Inc. is enhancing its engagement with the European financial and healthcare sectors by participating in three significant events, following the announcement of a potential third therapeutic indication for its lead drug asset, ExoPTEN [1][5] Group 1: Upcoming Events and Participation - CEO Dr. Lior Shaltiel will represent NurExone at INVEST 2025 in Stuttgart, a key investment conference for German-speaking markets, where the company will present its corporate strategy and pipeline development [2][3] - NurExone is also participating in the Healthtech Roadshow in Zurich from May 5-8, 2025, aimed at engaging healthcare professionals and life science investors in Switzerland [3] - From May 12-15, 2025, Dr. Shaltiel will present at BioProcess International Europe in Hamburg, discussing the company's exosome-based siRNA therapy and its ExoTherapy platform [4] Group 2: Strategic Goals and Growth Narrative - The participation in these events is designed to increase visibility for NurExone's innovative approach to regenerative medicine, particularly with the identification of a third potential indication for ExoPTEN, which enhances the company's growth narrative [5] - NurExone plans to maintain an active presence at key European conferences throughout 2025 to strengthen investor relations and foster strategic collaborations in the healthcare and biotech sectors [6] Group 3: Company Overview and Product Focus - NurExone Biologic Inc. is focused on developing exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing promising preclinical data for treating spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [7] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe, and has established Exo-Top Inc. as a U.S. subsidiary to support its North American growth strategy [7]